Show simple item record

dc.contributor.authorHo, Duy-Khiet
dc.contributor.authorNichols, Brittany L B
dc.contributor.authorEdgar, Kevin J
dc.contributor.authorMurgia, Xabier
dc.contributor.authorLoretz, Brigitta
dc.contributor.authorLehr, Claus-Michael
dc.date.accessioned2019-09-13T13:59:50Z
dc.date.available2019-09-13T13:59:50Z
dc.date.issued2019-09-04
dc.identifier.citationEur J Pharm Biopharm. 2019 Sep 4. pii: S0939-6411(19)30620-4. doi: 10.1016/j.ejpb.2019.09.002.en_US
dc.identifier.issn1873-3441
dc.identifier.pmid31493510
dc.identifier.doi10.1016/j.ejpb.2019.09.002
dc.identifier.urihttp://hdl.handle.net/10033/621937
dc.description.abstractInhalation therapy has been reported as the most effective treatment for respiratory bacterial infections due to the increasing relevance of drug bioavailability. Drug delivery systems (DDS) have the capacity to overcome pulmonary biological barriers limiting the bioavailability of inhaled anti-infectives. This is important to eradicate bacterial infections and to prevent the development of bacterial resistance. Despite substantial efforts in the field, the current state-of-the-art often fails to achieve those goals, and we still observe increasing bacterial resistance. We give a brief insight on benefits and challenges in pulmonary delivery of anti-infectives. In the context of drug delivery development for pulmonary infections, particularly focusing on Pseudomonas aeruginosa (PA) infections, this mini review will critically discuss the main requirements, as well as the recent strategies of drug delivery system synthesis and preparation. Finally, interaction of DDS with crucial pulmonary biological barriers will be of great importance for the success of future applications of the developed DDS.en_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.rightsAttribution-NonCommercial-ShareAlike 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subjectPseudomonas aeruginosaen_US
dc.subjectanti-infectivesen_US
dc.subjectantibioticsen_US
dc.subjectbiofilmen_US
dc.subjectbiological barriersen_US
dc.subjectdrug deliveryen_US
dc.subjectmucusen_US
dc.subjectnanomedicineen_US
dc.subjectnanoparticlesen_US
dc.subjectpulmonary infectionsen_US
dc.subjectquorum sensing inhibitoren_US
dc.titleChallenges and Strategies in Drug Delivery Systems for Treatment of Pulmonary Infections.en_US
dc.typeArticleen_US
dc.contributor.departmentHIPS, Helmholtz-Institut für Pharmazeutische Forschung Saarland, Universitätscampus E8.1 66123 Saarbrücken, Germany.en_US
dc.identifier.journalEuropean Journal of Pharmaceutics and Biopharmaceuticsen_US
dc.source.journaltitleEuropean journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V


Files in this item

Thumbnail
Name:
Publisher version
Thumbnail
Name:
Ho et al.pdf
Size:
893.6Kb
Format:
PDF
Description:
original manuscript

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-ShareAlike 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International